Citations

Clear

3501 citation(s) found for "Xu, Timothy".

Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease
Huang, Yannan , Sompii‐Montgomery, Laura, Patti, Jessica, Pickering, Alex, Yasin, Shima , Gao, Denny , Abdul‐Aziz, Rabheh , Behrens, Edward M. , Co, Dominic O. , Collins, Kathleen , Eberhard, B. Anne, Friedman, Monica, Graham, T. Brent , Hahn, Timothy , Hersh, Aimee O. , Hobday, Patricia M. , Holland, Michael J., Huggins, Jennifer , Lu, Pai‐Yue, Mannion, Melissa L. , Manos, Cynthia K., Neely, Jessica , Ramirez, Andrea, Reinhardt, Adam, Riskalla, Mona , Santiago, L E, Ting, Tracy V. , Grom, Alexei A. , Towe, C. , Gao, Denny , Canna, Scott , Hersh, Aimee O , Mannion, Melissa L , Neely, Jessica , Schulert, Grant S , Behrens, Edward M , Do, Thuy, Baker, Elizabeth K. , Clark, Matthew, Collins, Kathleen , Holland, Michael J., Onel, Karen , Orandi, Amir B. , Stoll, Matthew Laurence

Mayo Clinic

Arthritis Care & Research | September 11, 2023 | Volume: 76 | Issue: 3 | Pages: 328-339

10.1002/acr.25234 | PMID 37691306 Get It

Objective Systemic juvenile idiopathic arthritis–associated lung disease (SJIA‐LD) is a life‐threatening disease complication. Key questions remain regarding clinical course and optimal treatment approaches. The objectives of the study were to detail management strategies after SJIA‐LD detection, characterize overall disease courses, and measure long‐term outcomes. Methods This was a prospective cohort study. Clinical data were abstracted from the electronic medical record, including current clinical status and changes since diagnosis. Serum biomarkers were determined and correlated with presence of LD. Results We enrolled 41 patients with SJIA‐LD, 85% with at least one episode of macrophage activation syndrome and 41% with adverse reactions to a biologic. Although 93% of patients were alive at last follow‐up (median 2.9 years), 37% progressed to requiring chronic oxygen or other ventilator support, and 65% of patients had abnormal overnight oximetry studies, which changed over time. Eighty‐four percent of patients carried the HLA‐DRB1*15 haplotype, significantly more than patients without LD. Patients with SJIA‐LD also showed markedly elevated serum interleukin‐18 (IL‐18), variable C‐X‐C motif chemokine ligand 9 (CXCL9), and significantly elevated matrix metalloproteinase 7. Treatment strategies showed variable use of anti–IL‐1/6 biologics and addition of other immunomodulatory treatments and lung‐directed therapies. We found a broad range of current clinical status independent of time from diagnosis or continued biologic treatment. Multidomain measures of change showed imaging features were the least likely to improve with time. Conclusion Patients with SJIA‐LD had highly varied courses, with lower mortality than previously reported but frequent hypoxia and requirement for respiratory support. Treatment strategies were highly varied, highlighting an urgent need for focused clinical trials.
OS09.4.A RANO 2.0: UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
Wen, Patrick Y. , Youssef, George , Barboriak, Daniel P. , DeGroot, John, Lassman, Andrew B. , Molinaro, Annette M. , Rahman, Rifaquat , Shankar, Lalitha , Sul, Joohee, Villanueva‐Meyer, Javier , Macdonald, David , Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , Barboriak, Daniel P , Wen, Patrick Yung , Bent, Martin J. van den , Youssef, G, Cloughesy, Timothy F. , Ellingson, Benjamin M. , Weller, Michael , Galanis, Evanthia , Gilbert, Mark R. , Huang, Raymond Y. , Mehta, Minesh P. , Molinaro, Annette M. , Preusser, Matthias , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii21-ii21

10.1093/neuonc/noad137.061 Get It

Abstract BACKGROUND The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time some limitations of these criteria were identified, and uncertainty emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. MATERIAL AND METHODS Informed by data from a cohort of glioblastoma patients and other evaluations of RANO criteria that allowed evaluation of features of the different criteria, the RANO working group developed updates to the RANO criteria (RANO 2.0). RESULTS Based on the 2021 WHO classification of gliomas, we recommend a standard set of criteria for both high and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the post-radiotherapy MRI, rather than the post-surgical MRI, will be used as the baseline for future comparison. Since the incidence of pseudoprogression is high in the 12 weeks following radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, is required to define tumor progression. However, confirmation scans are not mandatory after this period nor for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (2-dimensional) but volumetric measurements are an option. For IDH-wildtype glioblastoma, the non-enhancing disease will no longer be evaluated. In IDH-mutated tumors with a significant non-enhancing component, clinical trials may require evaluating both the enhancing and non-enhancing tumor components for response assessment. CONCLUSION These criteria represent a work in progress that will hopefully improve the assessment of response in glioma trials. Future updates will incorporate novel developments, advanced imaging techniques, and endpoints as they become validated.
Rechallenge With Switching Immune Checkpoint Inhibitors Following Autoimmune Myocarditis in a Patient With Lynch Syndrome
Eslinger, Cody , Walden, Daniel , Barry, Timothy , Shah, Shimoli , Samadder, N. Jewel , Bekaii‐Saab, Tanios , Samadder, Niloy Jewel, Bekaii-Saab, Tanios S

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 6, 2023 | Volume: 21 | Issue: 9 | Pages: 894-899

10.6004/jnccn.2023.7029 | PMID 37673116 Get It

Immune checkpoint inhibitors (ICIs) induce profound benefits in cancer patients with mismatch repair gene mutations or high levels of microsatellite instability. Herein, we present a case of a patient with history of Muir-Torre/Lynch syndrome and metastatic gastric adenocarcinoma in the presence of an MSH2 gene mutation. The patient was initially treated with a PD-1 inhibitor, pembrolizumab, but developed grade 4 myocarditis requiring treatment with infliximab and a prolonged steroid taper. Following discontinuation of pembrolizumab, surveillance testing showed no radiographic or endoscopic evidence of progression for 7 months, until biopsy results from a repeat upper endoscopy indicated local disease recurrence. The patient was subsequently rechallenged with another PD-1 inhibitor, nivolumab, at a 50% dose reduction without recurrent adverse events and eventually achieved a complete response after 13 cycles. This case highlights the relative importance of considering careful rechallenge with ICI therapy in patients with microsatellite instability–high malignancies and a high risk of severe adverse events.
Characterization of single‐ and multi‐energy CT performance of an oral dark borosilicate contrast media using a clinical photon‐counting‐detector CT platform
Ren, Liqiang , Sun, Yuxin , Yeh, Benjamin M. , Marsh, Jeffrey F., Winfree, Timothy, Burke, Kristin A., Mileto, Achille , Winfree, Timothy N, Rajendran, Kishore , McCollough, Cynthia H. , Fletcher, Joel G. , Leng, Shuai

Mayo Clinic

Medical Physics | September 5, 2023 | Volume: 50 | Issue: 11 | Pages: 6779-6788

10.1002/mp.16713 | PMID 37669507 Get It

AbstractBackgroundThe feasibility of oral dark contrast media is under exploration in abdominal computed tomography (CT) applications. One of the experimental contrast media in this class is dark borosilicate contrast media (DBCM), which has a CT attenuation lower than that of intra‐abdominal fat.PurposeTo evaluate the performances of DBCM using single‐ and multi‐energy CT imaging on a clinical photon‐counting‐detector CT (PCD‐CT).MethodsFive vials, three with iodinated contrast agent (5, 10, and 20 mg/mL; Omnipaque 350) and two with DBCM (6% and 12%; Nextrast, Inc.), and one solid‐water rod (neutral contrast agent) were inserted into two multi‐energy CT phantoms, and scanned on a clinical PCD‐CT system (NAEOTOM Alpha) at 90, 120, 140, Sn100, and Sn140 kV (Sn: tin filter) in multi‐energy mode. CARE keV IQ level was 180 (CTDIvol: 3.0 and 12.0 mGy for the small and large phantoms, respectively). Low‐energy threshold images were reconstructed with a quantitative kernel (Qr40, iterative reconstruction strength 2) and slice thickness/increment of 2.0/2.0 mm. Virtual monoenergetic images (VMIs) were reconstructed from 40 to 140 keV at 10 keV increments. On all images, average CT numbers for each vial/rod were measured using circular region‐of‐interests and averaged over eight slices. The contrast‐to‐noise ratio (CNR) of iodine (5 mg/mL) against DBCM was calculated and plotted against tube potential and VMI energy level, and compared to the CNR of iodine against water. Similar analyses were performed on iodine maps and VNC images derived from the multi‐energy scan at 120 kV.ResultsWith increasing kV or VMI keV, the negative HU of DBCM decreased only slightly, whereas the positive HU of iodine decreased across all contrast concentrations and phantom sizes. CT numbers for DBCM decreased from −178.5 ± 9.6 to −194.4 ± 6.3 HU (small phantom) and from −181.7 ± 15.7 to −192.1 ± 11.9 HU (large phantom) for DBCM‐12% from 90 to Sn140 kV; on VMIs, the CT numbers for DBCM decreased minimally from −147.1 ± 15.7 to −185.1 ± 9.2 HU (small phantom) and −158.8 ± 28.6 to −188.9 ± 14.7 HU (large phantom) from 40 to 70 keV, but remained stable from 80 to 140 keV. The highest iodine CNR against DBCM in low‐energy threshold images was seen at 90 or Sn140 kV for the small phantom, whereas all CNR values from low‐energy threshold images for the large phantom were comparable. The CNR values of iodine against DBCM computed on VMIs were highest at 40 or 70 keV depending on iodine and DBCM concentrations. The CNR values of iodine against DBCM were consistently higher than iodine to water (up to 460% higher dependent on energy level). Further, the CNR of iodine compared to DBCM is less affected by VMI energy level than the identical comparison between iodine and water: CNR values at 140 keV were reduced by 46.6% (small phantom) or 42.6% (large phantom) compared to 40 keV; CNR values for iodine compared to water were reduced by 86.3% and 83.8% for similar phantom sizes, respectively. Compared to 70 keV VMI, the iodine CNR against DBCM was 13%–79% lower on iodine maps and VNC.ConclusionsWhen evaluated at different tube potentials and VMI energy levels using a clinical PCD‐CT system, DBCM showed consistently higher CNR compared to iodine versus water (a neutral contrast).
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
Adappa, Nithin D. , Beswick, Daniel M. , London, Nyall R. , Su, Shirley Y. , Wang, Marilene B. , Alexiev, Borislav A. , Antognoni, Paolo , Alonso‐Basanta, Michelle , Batra, Pete S., Bhayani, Mihir K. , Bell, Diana , Betz, Christian , Callejas, Claudio , Casiano, Roy R. , Chatzinakis, Vasileios , Chen, Simon , Chowdhury, Naweed I. , Citardi, Martin J. , Cohen, Marc A. , Dagan, Roi , Dalfino, Gianluca , Dassi, Camila , Almeida, John R. de , Tos, Angelo Paolo Dei , DelGaudio, John M. , Ebert, Charles S. , Eloy, Jean Anderson , Evans, James J., Fang, Christina H. , Farrell, Nyssa Fox , Ferrari, Marco , Fischbein, Nancy J. , Folbe, Adam J. , Fox, Meha G. , Lund, Valerie J. , Gallia, Gary L. , Gardner, Paul A. , Getz, Anne E., Govindaraj, Satish, Gray, Stacey T. , Gross, Bradley A. , Guo, Ruifeng , Ha, Patrick K. , Halderman, Ashleigh A. , Hanna, Ehab Y., Harvey, Richard J. , Hernandez, Stephen, Hopkins, Claire , Huang, Zhigang , Huang, Zhenxiao , Humphreys, Ian M. , Hwang, Peter H. , Iloreta, Alfred Marc, Ishii, Masaru , Jafari, Aria , Kennedy, David W. , Khan, Mohemmed, Kimple, Adam J. , Kingdom, Todd T. , Knisely, Anna, Kuo, Ying‐Ju , Lamarre, Eric , Lan, Ming‐Ying , Le, Hien , Lee, Nancy Y. , Lee, Jivianne K., Lee, Victor , Levine, Corinna G. , Lin, Jin‐Ching , Lin, Derrick T., Locke, Tran B. , Luong, Amber , Magliocca, Kelly R. , Matnjani, G., Meço, Cem , Michel, Loren S. , Na'ara, Shorook, Nicolai, Piero , Nuss, Daniel W. , Nyquist, Gurston , Oakley, Gretchen M. , Omura, Kazuhiro , Orlandi, Richard R. , Otori, Nobuyoshi , Papagiannopoulos, Peter , Patel, Zara M. , Pfister, David G. , Rabinowitz, Mindy, Sanusi, Olabisi , Sargi, Zoukaa , Schafhausen, Philippe, Schlosser, Rodney J. , Sedaghat, Ahmad R. , Senior, Brent A. , Shrivastava, Raj , Sindwani, Raj , Smith, Timothy L. , Smith, Kristine A. , Solares, C. Arturo , Stamm, Aldo Cassol , Stölzel, Katharina , Sumer, Baran D. , Tajudeen, Bobby A. , Thorp, Brian D. , Tsang, Raymond K. , VanKoevering, Kyle K. , Welch, Kevin C. , Wise, Sarah K. , Witterick, Ian , Won, Tae‐Bin , Wong, Stéphanie , Woodworth, Bradford A. , Wormald, Peter‐John , Zhou, Bing , Adappa, Nithin D. , Chapurin, Nikita , Ayoub, Noel , Bitner, Benjamin F. , Chang, Michael T. , Kuan, Edward C , Wang, Eric W , Beswick, Daniel , Wang, Marilene B , Alt, Jeremiah A , Bleier, Benjamin , Callejas, Claudio , Choby, Garret , Dalfino, Gianluca , Eloy, Jean Anderson , Fang, Christina H , Farrell, Nyssa F , Ferrari, Marco , Georgalas, Christos , Grayson, Jessica W , Harvey, Richard J , Holtzman, Adam L. , Hopkins, Claire , Humphreys, Ian M , Hwang, Peter H , Jafari, Aria , Kimple, Adam J , Lal, Devyani , Lan, Ming-Ying , Luong, Amber U , Meço, Cem , Omura, Kazuhiro , Orlandi, Richard , Patel, Zara , Sedaghat, Ahmad R , Senior, Brent A , Smith, Timothy L , Smith, Kristine , Snyderman, Carl H , Tong, Charles C L , van Zele, Thibaut , Won, Tae-Bin , Woodworth, Bradford A , Yao, William C , Yeh, Chien-Fu , Zhou, Bing , Schlosser, Rodney J , Bitner, Benjamin , Guo, Ruifeng , Chang, Michael T , Su, Shirley Y , Locke, Tran Bao , Adappa, Nithin D. , Abuzeid, Waleed M. , Alt, Jeremiah A. , Bernal‐Sprekelsen, Manuel , Blay, Jean‐Yves , Bleier, Benjamin S. , Bonilla‐Velez, Juliana , Carrau, Ricardo L. , Castelnuovo, Paolo , Chandra, Rakesh Kumar , Chiu, Alexander G. , Choby, Garret , Dallan, Iacopo , El‐Sayed, Ivan H. , Fokkens, Wytske Johanna , Geltzeiler, Mathew , Grayson, Jessica W. , Gross, Bradley , Grube, Jordon G. , Hanna, Ehab Y., Ivan, Michael E , Khan, Mohemmed N., Lal, Devyani , Lechner, Matt , Lobo, Brian C. , Markovic, Svetomir N. , McKean, Erin L. , Mendenhall, William M , Phan, Jack , Psaltis, Alkis J. , Ramanathan, Murugappan , Rimmer, Ryan , Rosen, Marc R , Sreenath, Satyan B , Šurda, Pavol , Thompson, Lester D.�R. , Turner, Justin H. , Turri‐Zanoni, Mario , Udager, Aaron M , Yao, William C.

Mayo Clinic

International Forum of Allergy & Rhinology | September 2, 2023 | Volume: 14 | Issue: 2 | Pages: 149-608

10.1002/alr.23262 | PMID 37658764 Get It

Abstract Background Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field. Methods In accordance with prior International Consensus Statement on Allergy and Rhinology documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on the level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication. Results The ICSNT document consists of four major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention. Conclusion As an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.
Aging in females is associated with changes in respiratory modulation of sympathetic nerve activity and blood pressure
Adams, Zoe H. , Blythe, Hazel , Charkoudian, Nisha , Joyner, Michael J. , Kendrick, Adrian , Nightingale, Angus K. , Abdala, Ana P. , Hart, Emma C. , Blythe, Hazel C , Curry, Timothy B. , Joyner, Michael J , Nightingale, Angus K , Abdala Sheikh, Ana P , Hart, Emma C

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | September 1, 2023 | Volume: 325 | Issue: 5 | Pages: H1108-H1117

10.1152/ajpheart.00226.2023 | PMID 37656132 Get It

The current study demonstrates that respiratory modulation of sympathetic nerve activity (SNA) is reduced in healthy postmenopausal (PMF) versus premenopausal females (YF). Furthermore, respiratory sympathetic modulation was negatively related to resting blood pressure in postmenopausal females, such that blood pressure was greater in individual with less modulation. Reduced respiratory sympathetic modulation may have implications for the autonomic control of blood pressure in aging postmenopausal females, by contributing to age-related sympathetic activation and reducing acute, respiratory-linked blood pressure variation.
The dependence of maximum oxygen uptake and utilization (V̇O2max) on hemoglobin‐oxygen affinity and altitude
Webb, Kevin L. , Joyner, Michael J. , Wiggins, Chad C. , Secomb, Timothy W. , Roy, Tuhin K , Wiggins, Chad C , Joyner, Michael J , Secomb, Timothy W , Webb, Kevin L , Roy, Tuhin K.

Mayo Clinic

Physiological Reports | September 1, 2023 | Volume: 11 | Issue: 17 | Pages: No page available

10.14814/phy2.15806 | PMID 37653565 Get It

AbstractOxygen transport from the lungs to peripheral tissue is dependent on the affinity of hemoglobin for oxygen. Recent experimental data have suggested that the maximum human capacity for oxygen uptake and utilization (V̇O2max) at sea level and altitude (~3000 m) is sensitive to alterations in hemoglobin‐oxygen affinity. However, the effect of such alterations on V̇O2max at extreme altitudes remains largely unknown due to the rarity of mutations affecting hemoglobin‐oxygen affinity. This work uses a mathematical model that couples pulmonary oxygen uptake with systemic oxygen utilization under conditions of high metabolic demand to investigate the effect of hemoglobin‐oxygen affinity on V̇O2max as a function of altitude. The model includes the effects of both diffusive and convective limitations on oxygen transport. Pulmonary oxygen uptake is calculated using a spatially‐distributed model that accounts for the effects of hematocrit and hemoglobin‐oxygen affinity. Systemic oxygen utilization is calculated assuming Michaelis–Menten kinetics. The pulmonary and systemic model components are solved iteratively to compute predicted arterial and venous oxygen levels. Values of V̇O2max are predicted for several values of hemoglobin‐oxygen affinity and hemoglobin concentration based on data from humans with hemoglobin mutations. The model predicts that increased hemoglobin‐oxygen affinity leads to increased V̇O2max at altitudes above ~4500 m.
Three-Dimensional Transesophageal Echocardiography in Percutaneous Catheter-Based Cardiac Interventions
Farina, Juan M. , Barry, Timothy , Arsanjani, Reza , Naqvi, Tasneem Z. , Naqvi, Tasneem Z , Arsanjani, Reza , Farina, Juan M

Mayo Clinic

Journal of Clinical Medicine | August 31, 2023 | Volume: 12 | Issue: 17 | Pages: 5664

10.3390/jcm12175664 | PMID 37685731 Get It

Cardiac structural and valve interventions have remained surgical procedures for several decades. The ability to directly visualize the region of interest during surgery made imaging of these structures pre- and postsurgery a secondary tool to compliment surgical visualization. The last two decades, however, have seen rapid advances in catheter-based percutaneous structural heart interventions (SHIs). Due to the “blind” nature of these interventions, imaging plays a crucial role in the success of these procedures. Fluoroscopy is used universally in all percutaneous cardiac SHIs and helps primarily in the visualization of catheters and devices. However, success of these procedures requires visualization of intracardiac soft tissue structures. Due to its portable nature and rapid ability to show cardiac structures online, transesophageal echocardiography (TEE) has become an integral tool for guidance for all percutaneous SHI. Transcatheter aortic valve replacement—one of the earliest catheter-based procedures—while initially dependent on TEE, has largely been replaced by preprocedural cardiac CT for accurate assessment of valve sizing. Developments in echocardiography now allow live three-dimensional (3D) visualization of cardiac structures mimicking surgical anatomy during TEE. Besides showing actual 3D intracardiac structures, 3D-TEE allows visualization of the interaction of intracardiac catheters and devices with soft tissue cardiac structures, thereby becoming a “second pair of eyes” for the operator. Real-time 3D-TEE now plays an important role complementing multiplane two dimensional and biplane TEE during such interventions. In this review, we discuss the incremental role of 3D-TEE during various SHIs performed today.
Predictive factors for decreased baseline quality of life in patients with sinonasal malignancies
Fleseriu, Cara M. , Beswick, Daniel M. , Maoz, Sabrina L. , Hwang, Peter H. , Chan, Erik, Adappa, Nithin D. , Getz, Anne E., Humphries, Ian M., Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Nabavizadeh, Seyed Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Jay, Wang, Marilene B. , Choby, Garret , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Wang, Eric W , Beswick, Daniel , Hwang, Peter H , Maoz, Sabrina L , Choby, Garret , Adappa, Nithin D. , Geltzeiler, Mathew , Humphreys, Ian M. , Le, Christopher H. , Abuzeid, Waleed M. , Lee, Jivianne K., Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D.

Mayo Clinic

International Forum of Allergy & Rhinology | August 30, 2023 | Volume: 14 | Issue: 4 | Pages: 775-785

10.1002/alr.23261 | PMID 37646428 Get It

AbstractBackgroundThe impact of sinonasal malignancies (SNMs) on quality of life (QOL) at presentation is poorly understood. The Sinonasal Outcome Test (SNOT‐22) and University of Washington Quality of Life (UWQOL) are validated QOL instruments with distinctive subdomains. This study aims to identify factors impacting pretreatment QOL in SNM patients to personalize multidisciplinary management and counseling.MethodsPatients with previously untreated SNMs were prospectively enrolled (2015–2022) in a multicenter observational study. Baseline pretreatment QOL instruments (SNOT‐22, UWQOL) were obtained along with demographics, comorbidities, histopathology/staging, tumor involvement, and symptoms. Multivariable regression models identified factors associated with reduced baseline QOL.ResultsAmong 204 patients, presenting baseline QOL was significantly reduced. Multivariable regression showed worse total SNOT‐22 QOL in patients with skull base erosion (p = 0.02). SNOT‐rhinologic QOL was worse in women (p = 0.009), patients with epistaxis (p = 0.036), and industrial exposure (p = 0.005). SNOT extranasal QOL was worse in patients with industrial exposure (p = 0.016); worse SNOT ear/facial QOL if perineural invasion (PNI) (p = 0.027). Squamous cell carcinoma pathology (p = 0.037), palate involvement (p = 0.012), and pain (p = 0.017) were associated with worse SNOT sleep QOL scores. SNOT psychological subdomain scores were significantly worse in patients with palate lesions (p = 0.022), skull base erosion (p = 0.025), and T1 staging (p = 0.023). Low QOL was more likely in the presence of PNI on UW health (p = 0.019) and orbital erosion on UW overall (p = 0.03). UW social QOL was worse if palatal involvement (p = 0.023) or PNI (p = 0.005).ConclusionsOur findings demonstrate a negative impact on baseline QOL in patients with SNMs and suggest sex‐specific and symptom‐related lower QOL scores, with minimal histopathology association. Anatomical tumor involvement may be more reflective of QOL than T‐staging, as orbital and skull base erosion, PNI, and palate lesions are significantly associated with reduced baseline QOL.
Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration
Farina, Juan M. , Pereyra, Milagros , Roarke, Michael C., Said, Ebram F, Barry, Timothy , Sweeney, John P., Fortuin, David, Lester, Steven J., Oh, Jae K. , Marcotte, François , Roarke, Michael, Sell-Dottin, Kristen, Fortuin, David F, Farina, Juan M , Pereyra, Milagros , Chao, Chieh‐Ju , Alsidawi, Said , Sell‐Dottin, Kristen , Arsanjani, Reza

Mayo Clinic

Heart | August 29, 2023 | Volume: 110 | Issue: 4 | Pages: 299-305

10.1136/heartjnl-2023-322987 | PMID 37643771 Get It

Objectives Lipoprotein(a) (Lp(a)) is associated with an increased incidence of native aortic stenosis, which shares similar pathological mechanisms with bioprosthetic aortic valve (bAV) degeneration. However, evidence regarding the role of Lp(a) concentrations in bAV degeneration is lacking. This study aims to evaluate the association between Lp(a) concentrations and bAV degeneration. Methods In this retrospective multicentre study, patients who underwent a bAV replacement between 1 January 2010 and 31 December 2020 and had a Lp(a) measurement were included. Echocardiography follow-up was performed to determine the presence of bioprosthetic valve degeneration, which was defined as an increase >10 mm Hg in mean gradient from baseline with concomitant decrease in effective orifice area and Doppler Velocity Index, or new moderate/severe prosthetic regurgitation. Levels of Lp(a) were compared between patients with and without degeneration and Cox regression analysis was performed to investigate the association between Lp(a) levels and bioprosthetic valve degeneration. Results In total, 210 cases were included (mean age 74.1±9.4 years, 72.4% males). Median time between baseline and follow-up echocardiography was 4.4 (IQR 3.7) years. Bioprostheses degeneration was observed in 33 (15.7%) patients at follow-up. Median serum levels of Lp(a) were significantly higher in patients affected by degeneration versus non-affected cases: 50.0 (IQR 72.0) vs 15.6 (IQR 48.6) mg/dL, p=0.002. In the regression analysis, high Lp(a) levels (≥30 mg/dL) were associated with degeneration both in a univariable analysis (HR 3.6, 95% CI 1.7 to 7.6, p=0.001) and multivariable analysis adjusted by other risk factors for bioprostheses degeneration (HR 4.4, 95% CI 1.9 to 10.4, p=0.001). Conclusions High serum Lp(a) is associated with bAV degeneration. Prospective studies are needed to confirm these findings and to investigate whether lowering Lp(a) levels could slow bioprostheses degradation.